

Supplementary Table 4 Summary of combined CTLA-4 and PD-1 inhibitor therapy related renal toxicities

<i>Publication</i>	<i>Patient Number</i>	<i>Regimen</i>	<i>Time of onset</i>	<i>Type of Cancer</i>	<i>Age (y)</i>	<i>Gender</i>	<i>Renal Pathology</i>	<i>Renal Outcomes</i>	<i>Cancer Outcome</i>
Cortazar et al	1	Ipi + Nivo	12 weeks	Melanoma	64	Male	Granulomatous AIN	Steroids given with complete recovery	NA
Cortazar et al	2	Ipi +Nivo	10 weeks	Melanoma	74	Male	Granulomatous AIN	Partial recovery with steroids and needed dialysis as well	NA
Cortazar et al	3	Ipi+Nivo	33 weeks	Melanoma	71	Male	Diffuse AIN	Partial recovery with steroids	NA
Cortazar et al	4	Ipi+Nivo	7 weeks	Melanoma	75	Male	Diffuse AIN	Partial recovery with steroids	NA
Murakami et al	5	Ipi+Nivo	5 weeks	Melanoma	75	Male	Diffuse AIN	Partial recovery with steroids	NA

Supplementary Online Appendix for article for Wanchoo R et al. " Adverse Renal Effects of Immune Check Point Inhibitors: A Narrative Review."

Shirali et al	6	Ipi+Nivo	6 months	NSCLC	59	Male	Focal AIN, tubular vacuolization	<p>Creatinine 1.3mg/dl after discontinuation of both agents</p> <p>Creatinine 10.4mg/dl when nivolumab restarted 2 months later, Treatment: Steroids for 1 month, serum creatinine decreased to 1.4mg/dl</p>	NA
---------------	---	----------	----------	-------	----	------	----------------------------------	--	----

AIN: acute interstitial nephritis; AKI: Acute kidney injury; Nivo: Nivolumab, Ipi: Ipilimumab; NA: Not available